Latest Bicifadine Stories
XTL Biopharmaceuticals, a developer of therapeutics for the treatment of diabetic neuropathic pain and hepatitis C virus, has announced that the last patient randomized into the Bicifadine Phase IIb clinical trial for the treatment of diabetic neuropathic pain has completed the study.
VALLEY COTTAGE, N.Y., Aug. 14 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. today announced that Samuel H. Rudman, Esq., has been appointed to XTL's Board of Directors, effective as of August 13, 2008. Mr. Rudman, 40, is a named partner at a U.S.
XTL Biopharmaceuticals has completed patient randomization into its Phase IIb study of Bicifadine - a serotonin and norepinephrine reuptake inhibitor - for the treatment of diabetic neuropathic pain. Approximately 350 patients were randomized into the study.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.